✦ LIBER ✦

Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source

✍ Scribed by Wayne M. Koch; Nassir Bhatti; Mark F. Williams; David W. Eisele

Book ID: 117843541
Publisher: SAGE Publications
Year: 2001
Tongue: English
Weight: 45 KB
Volume: 124
Category: Article
ISSN: 0194-5998
DOI: 10.1067/mhn.2001.114309

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Management of unknown primary head and n

Management of unknown primary head and neck squamous cell carcinoma

✍ Chih-Yu Hsing; Shi-An Liu; Chen-Chi Wang 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Prognostic factors of unknown primary he

Prognostic factors of unknown primary head and neck squamous cell carcinoma

✍ Chun-Chi Huang; Fen-Yu Tseng; Te-Huei Yeh; Yu-Hsuan Wen; Chuang-Jen Hsu; Jeng-Yu 📂 Article 📅 2008 🏛 SAGE Publications 🌐 English ⚖ 95 KB

Role of tonsillectomy in the search for

Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck

✍ Prasad Kothari; Premjit S. Randhawa; Roy Farrell 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 424 KB

Commentary on “Management of unknown pri

Commentary on “Management of unknown primary head and neck squamous cell carcinoma”

✍ William M. Mendenhall 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Unknown primary squamous cell carcinoma

Unknown primary squamous cell carcinoma of the head and neck: is mucosal irradiation necessary?

✍ Debra Freeman; William M. Mendenhall; James T. Parsons; Rodney R. Million 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 234 KB

Benefit of postoperative chemoradiothera

Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck

✍ Nasfat J. Shehadeh; John F. Ensley; Omer Kucuk; Carri Black; George H. Yoo; John 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

Background. Postopertative adjuvant chemoradiotherapy recently became an established modality for patients with selected high-risk locally advanced head and neck cancers. The optimal treatment of unknown primary squamous cell cancer of the head and neck (SCCHN) continues to be controversial, since m